Novacyt H1 2026 loss after tax narrows 9% to GBP 5.79 million; revenue rises 18% to GBP 11.56 million
Bitget2026/09/30 07:37- Novacyt posted a loss after tax attributable to owners of GBP 5.79 million for the six months ended June 30, 2026.
- Revenue rose 18% to GBP 11.56 million versus the six months ended June 30, 2025.
- Operating loss after other operating income/expense narrowed 29% to GBP 5.11 million.
- Net cash used in operating activities improved 17% to GBP 4.55 million, while cash and cash equivalents fell to GBP 8.92 million.
- The group acquired Southern Cross Diagnostics on March 2, 2026; it contributed GBP 1.84 million revenue and GBP 191,000 profit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
